bimekizumab sold brand name bimzelx humanized monoclonal used treat plaque psoriasis psoriatic arthritis axial spondyloarthritis ankylosing common side effects include upper respiratory tract infections nose throat infection oral candidiasis thrush fungal infection mouth injection site reactions also common reported bimekizumab approved medical use european union august united states october eu bimekizumab indicated treatment moderate severe plaque psoriasis active psoriatic arthritis nonradiographic axial spondyloarthritis active ankylosing bimekizumab developed belgian pharmaceutical company ucbcitation needed bimekizumab international nonproprietary name phase iii trials demonstrated bimekizumab superior also treatment plaque psoriasis immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding httpsenwikipediaorgwikibimekizumab